Abstract
Case The objective of this case report is to report a patient with moderate renal impairment who developed ertapenem-induced encephalopathy with delayed recovery of up to 2 weeks despite receiving and appropriately adjusted dosage of ertapenem. The patient was managed conservatively with full recovery. Carbapenem related neurotoxicity most commonly manifests as seizure with an estimated incidence of 3 %. There are increasing reports of encephalopathy being related to ertapenem and most commonly subsides within days and extended recovery of up to 2 weeks have only been reported in patients with end-stage renal failure. Conclusions Prolonged ertapenem induced encephalopathy can occur in patients with moderate renal impairment. These patients can be managed conservatively and they should make a complete recovery.
This is a preview of subscription content, log in via an institution to check access.
References
Hammond ML. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother. 2004;53 Suppl 2:ii7–9.
Odenholt I. Ertapenem: a new carbapenem. Expert Opin Investig Drugs. 2001;10:1157–66.
Duquaine S, Kitchell E, Tate T, Tannen RC, Wickremasinghe IM. Central nervous system toxicity associated with ertapenem use. Ann Pharmacother. 2011;45:e6.
Kuchinskas S, Reger C. Tactile hallucinations as a side effect of ertapenem on an acute rehabilitation floor. Am J Phys Med Rehabil. 2006;85:267.
Kong V, Beckert L, Awunor-Renner C. A case of beta lactam-induced visual hallucination. N Z Med J. 2009;122:76–7.
Wen MJ, Sung CC, Chau T, Lin SH. Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure. Clin Nephrol. 2012;. doi:10.5414/CN107247.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther. 1981;30:239–45.
Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Täuber MG. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother. 2003;47:1943–7.
Saidel-Odes L, Borer A, Riesenberg K, Smolyakov R, Schlaeffer F. History of cerebrovascular events: a relative contraindication to ertapenem treatment. Clin Infect Dis. 2006;43:262–3.
Liu X, Cheng MH, Shi CG, Wang C, Cheng CL, Chen JX, et al. Variability of glomerular filtration rate estimation equations in elderly Chinese patients with chronic kidney disease. Clin Interv Aging. 2012;7:409–15.
Funding
None.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Shea, Yf., Mok, My.M., Cheng, Kc. et al. Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism. Int J Clin Pharm 35, 535–537 (2013). https://doi.org/10.1007/s11096-013-9812-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-013-9812-x